---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000071"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T13:34:48.936306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LianBio's mavacamten meets primary endpoint in Phase 3 EXPLORER-CN trial; NDA accepted with Priority Review in China

## Summary
- EXPLORER-CN met primary endpoint: Valsalva LVOT gradient improvement from baseline to week 30 vs placebo (p<0.001).
- All secondary endpoints met, including resting LVOT gradient, NYHA class improvement, KCCQ-CSS, and LV mass index.
- Safety consistent with prior studies; no LVEF <50% requiring dose interruption.
- NDA for mavacamten accepted with Priority Review by China NMPA for symptomatic oHCM.
- LianBio to host analyst event May 1 to discuss topline data and China market opportunity.

## SEC filing metadata
- accession: 0001831283-23-000071
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000071/0001831283-23-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000071/lian-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000071
- JSON: https://secwatch.observer/filing/0001831283-23-000071.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.